CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease
- 10 November 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 3 (12), 1188-1196
- https://doi.org/10.1039/c1ib00018g
Abstract
Morphology specific nanobodies in conjunction with an electronic impedence biosensor can readily distinguish post-mortem CSF samples taken from human AD, PD andKeywords
This publication has 71 references indexed in Scilit:
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s diseaseActa Neuropathologica, 2010
- Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairmentActa Neuropathologica, 2010
- Detecting Morphologically Distinct Oligomeric Forms of α-SynucleinPublished by Elsevier BV ,2009
- Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaquesProceedings of the National Academy of Sciences of the United States of America, 2009
- Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α-Synuclein that Inhibits Aggregation and Prevents α-Synuclein-induced ToxicityJournal of Molecular Biology, 2007
- Relationships between the Sequence of α-Synuclein and its Membrane Affinity, Fibrillization Propensity, and Yeast ToxicityJournal of Molecular Biology, 2006
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementiaAnnals of Neurology, 2003
- Vesicle Permeabilization by Protofibrillar α-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's DiseaseBiochemistry, 2001